首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   3336篇
  免费   265篇
  国内免费   7篇
耳鼻咽喉   38篇
儿科学   84篇
妇产科学   72篇
基础医学   491篇
口腔科学   68篇
临床医学   367篇
内科学   697篇
皮肤病学   77篇
神经病学   353篇
特种医学   57篇
外科学   359篇
综合类   27篇
预防医学   412篇
眼科学   61篇
药学   233篇
中国医学   16篇
肿瘤学   196篇
  2024年   11篇
  2023年   72篇
  2022年   120篇
  2021年   232篇
  2020年   140篇
  2019年   149篇
  2018年   182篇
  2017年   108篇
  2016年   114篇
  2015年   102篇
  2014年   145篇
  2013年   167篇
  2012年   258篇
  2011年   265篇
  2010年   146篇
  2009年   121篇
  2008年   158篇
  2007年   157篇
  2006年   144篇
  2005年   137篇
  2004年   125篇
  2003年   90篇
  2002年   77篇
  2001年   20篇
  2000年   29篇
  1999年   21篇
  1998年   13篇
  1997年   14篇
  1996年   12篇
  1995年   15篇
  1993年   13篇
  1992年   12篇
  1991年   20篇
  1990年   21篇
  1989年   13篇
  1988年   15篇
  1987年   20篇
  1986年   14篇
  1985年   12篇
  1983年   10篇
  1982年   6篇
  1981年   12篇
  1979年   6篇
  1978年   7篇
  1977年   9篇
  1975年   8篇
  1974年   10篇
  1973年   7篇
  1972年   6篇
  1965年   6篇
排序方式: 共有3608条查询结果,搜索用时 593 毫秒
41.
42.
43.
44.
45.
46.
A racemic mixture of R and S enantiomers of praziquantel (PZQ) is currently the treatment of choice for schistosomiasis. Though the S enantiomer and the metabolites are presumed to contribute only a little to the activity of the drug, in-depth side-by-side studies are lacking. The aim of this study was to investigate the in vitro activities of PZQ and its main metabolites, namely, R- and S-cis- and R- and S-trans-4′-hydroxypraziquantel, against adult worms and newly transformed schistosomula (NTS). Additionally, we explored the in vivo activity and hepatic shift (i.e., the migration of the worms to the liver) produced by each PZQ enantiomer in mice. Fifty percent inhibitory concentrations of R-PZQ, S-PZQ, and R-trans- and R-cis-4′-hydroxypraziquantel of 0.02, 5.85, 4.08, and 2.42 μg/ml, respectively, for adult S. mansoni were determined in vitro. S-trans- and S-cis-4′-hydroxypraziquantel were not active at 100 μg/ml. These results are consistent with microcalorimetry data and studies with NTS. In vivo, single 400-mg/kg oral doses of R-PZQ and S-PZQ achieved worm burden reductions of 100 and 19%, respectively. Moreover, worms treated in vivo with S-PZQ displayed an only transient hepatic shift and returned to the mesenteric veins within 24 h. Our data confirm that R-PZQ is the main effector molecule, while S-PZQ and the metabolites do not play a significant role in the antischistosomal properties of PZQ.  相似文献   
47.
48.
One approach to fight against schistosomiasis is to develop an efficient vaccine. Schistosoma mansoni tetraspanning orphan receptor (SmTOR) might be a vaccine candidate, as it is a tegument membrane protein expressed most highly in cercariae. In this study we characterized the recombinant first extracellular domain of SmTOR (rSmTORed1) as having the expected property to bind C2 of complement similarly to a smaller peptide of the same domain, and to produce specific and high-titre antibodies in BALB/c mice immunized using complete Freund''s adjuvant/incomplete Freund''s adjuvant (CFA/IFA). Immunization was protective against parasite infection, as demonstrated by a significant decrease in worm burden in immunized BALB/c mice versus the control groups over two independent trials [64 and 45% reduction for mean adult worm burden in immunized versus phosphate-bufferd saline (PBS) injected mice]. Interestingly, infection by itself did not lead to the generation of anti-rSmTORed1 antibodies, corresponding to the low frequency of specific anti-rSmTORed1 antibodies detected in the sera of patients infected with S. mansoni (2/20; 10%). These data suggest that, as opposed to the natural infection during which SmTOR induces antibodies only rarely, immunization with its smaller first extracellular domain might be more efficient.  相似文献   
49.
The purpose of the current study was to identify effects of neurodevelopmental stimulation as administered by board certified music therapists to premature infants admitted to the neonatal intensive care unit. Premature infants (N = 108) admitted and meeting inclusion criteria were included. Experimental subjects received the developmental multimodal stimulation protocol paired with live singing (n = 25) or live singing with guitar accompaniment (n = 29). The no contact control group received standard neonatal intensive care unit care (n = 54). An ANCOVA analyses with birth weight as a covariate resulted in significant main effects found for infant length of stay (p < .05). When comparing the means, differences were found between gender and types of music paired with the developmental multimodal stimulation. The results of this study suggest an increase in neurodevelopment for infants receiving developmental multimodal stimulation as hypothesized.  相似文献   
50.
Objective: To measure the impact of race/ethnicity on cerclage efficacy, as measured by the prevalence of spontaneous preterm birth (PTB), in a cohort of patients with history-indicated, ultrasound-indicated and physical-exam indicated cerclages.

Methods: We conducted a retrospective cohort study of patients undergoing history-indicated, ultrasound-indicated and physical-exam indicated cerclage placement from January 2003 to July 2013 at a tertiary care hospital. Patients’ race/ethnicity was self-declared. Our primary outcome was spontaneous preterm birth (SPTB) Results: One hundred and eighty-one subjects met inclusion criteria. Forty-seven percent self-identified as non-Hispanic black (NHB), 12% as Hispanic and 41% as non-Hispanic white (NHW). There was no significant difference in the prevalence of SPTB p?=?0.22), nor for SPTB less than 34 or 28 weeks. Finally, there was no difference in SPTB prevalence by race after controlling for smoking, history of CKC/LEEP, and 17-OHPC with logistic regression.

Conclusion: Race/ethnicity does not appear to be associated with cerclage efficacy, as measured by the risk of SPTB, in a cohort of patients with history-indicated, ultrasound-indicated and physical-exam indicated cerclages.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号